# MoonLake Immunotherapeutics Announces Proposed Public Offering
Canonical URL: https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-announces-proposed-public-offering
Ticker: MLTX
Company: MoonLake Immunotherapeutics
Source: MoonLake Immunotherapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.moonlaketx.com
## Summary

ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed public offering of $150 million of its Class A ordinary

## Article Body
ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, today announced a proposed public offering of $150 million of its Class A ordinary
## Recent Company News
- 2026-06-25 13:46 EST — [MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering](https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-announces-pricing-of-upsized-200-million-public-offering) — Source: MoonLake Immunotherapeutics
- 2026-06-25 13:46 EST — [MoonLake Immunotherapeutics Announces Proposed Public Offering](https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-announces-proposed-public-offering) — Source: MoonLake Immunotherapeutics
- 2026-06-25 13:46 EST — [MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026](https://biopharmsignal.com/news/MLTX/moonlake-announces-week-52-results-of-sonelokimab-from-its-phase-3-vela-program-in-hidradenitis-suppurativa-and-confirms-investor-day-on-june-22-2026) — Source: MoonLake Immunotherapeutics
- 2026-06-25 13:46 EST — [MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-announces-positive-outcome-from-its-final-pre-bla-meeting-with-the-u-s-fda-and-reports-first-quarter-2026-financial-results) — Source: MoonLake Immunotherapeutics
- 2026-06-25 13:46 EST — [MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29](https://biopharmsignal.com/news/MLTX/moonlake-immunotherapeutics-to-host-a-capital-markets-day-on-tuesday-april-29) — Source: MoonLake Immunotherapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)